Home>>Histone H3K79Me3 (73-83) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt)

Histone H3K79Me3 (73-83) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt) (Synonyms: EIAQDF-K(Me3)-TDLR, H3K79me3, Histone H3 (73-83) (Lys79me3), H-Glu-Ile-Ala-Gln-Asp-Phe-Lys(Me3)-Thr-Asp-Leu-Arg-OH, Lys(Me3)79-Histone H3 (73-83))

Catalog No.GC43859

Histone H3K79Me3 (73-83) is a peptide fragment of histone H3 that corresponds to amino acid residues 74-84 of the human histone H3 sequence.

Products are for research use only. Not for human use. We do not sell to patients.

Histone H3K79Me3 (73-83) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
5mg
$856.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Histone H3K79Me3 (73-83) is a peptide fragment of histone H3 that corresponds to amino acid residues 74-84 of the human histone H3 sequence. Trimethylation of histone H3 at lysine 79 is found at promoter regions of both active and silenced genes in human CD4+ T cells and positively correlates with transcriptional repression. H3K79 trimethylation is also found at pericentromeric heterochromatin in mouse oocytes and somatic cells. Levels of H3K79Me3 are decreased in human tumor tissue compared to non-cancerous tissue.

Reviews

Review for Histone H3K79Me3 (73-83) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Histone H3K79Me3 (73-83) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.